ABSTRACT BACKGROUND Triple-negative breast cancer patients have no expression of Oestrogen Receptor (ER), Progesterone Receptor (PR) and there is neither expression nor amplification of human epidermal growth factor receptor 2 in a tumour. But non-triple negative breast cancer patients have either oestrogen receptor or progesterone receptor or both positive with or without amplification of Human epidermal growth factor receptor 2 in a tumour.
Based on gene expression profiles, breast cancer can be classified into 5 main groups. [5] [6] [7] [8]  Luminal A.  Luminal B.  Basal-like or Triple-negative.  Human epidermal growth factor receptor 2.  Normal breast-like. [6] [7] [8] [9] Triple-negative cancer occurs only if there is no expression of Oestrogen Receptor (ER), Progesterone Receptor (PR) and there is neither expression nor amplification of Human epidermal growth factor receptor 2 in a tumour. 10, 11 Basal-like tumours originate in the outer ("basal") cells that line the mammary ducts. Their incidence has been estimated to be between 13% and 25% [12] [13] of all breast cancer subtypes around the world 14, 15 and 10% -17% in western countries. 16 Triple-negative disease is diagnosed more frequently in younger and premenopausal women [17] [18] [19] [20] and is highly prevalent in African-American women reporting upto 30%. [21] [22] [23] [24] [25] They are often aggressive [26] [27] [28] and are associated with a prognosis poorer than those for the luminal A, luminal B and normal breast-like types. 27 Metastatically, they seem to disseminate to the axillary nodes and less frequently to bone.
Triple-negative cancer has attracted more attention, both clinically and experimentally because of its high-risk biological characteristics and lacking of effective treatment method. Patients with triple-negative cancer do not benefit from hormonal or targeted-based therapies because of the loss of target receptors such as ER, PR and HER-2. Hence, surgery chemotherapy and radiotherapy, individually or in combination appear to be the only available modalities. Triple-negative cancers are reported to respond to neoadjuvant chemotherapy, 9, 29, 30 but overall survival in patients with such tumours is still poor and management of these patients may require more aggressive treatment.
The human epidermal growth factor receptor 2 tumours are named for their status as HER2+. They tend to be ER-, PRand lymph node-positive with poorer grades. They may contain p53 mutations. The HER2+ have relatively poor prognoses and are prone to early and frequent relapse and to distant metastasis. 27, 31 The normal breast-like tumours are those that do not fall into any of the other categories. They account for 6% -10% of all breast cancers. These tumours are usually small and typically have a good prognosis. 32 They are more common in post-menopausal than in pre-menopausal women.
Objectives
To compare and analyse the clinico-pathological features, recurrence, metastasis and prognosis of patients with triplenegative breast cancer and non-triple-negative female breast cancer.
MATERIALS AND METHODS
Study Design-A retrospective descriptive study.
Study Setting
Department of Radiotherapy, TDMC, Alappuzha.
Study Period-January 1 st to December 31st 2011.
Sample Size 200 patients (100 patients from each arm).
All patients with tissue biopsy proved carcinoma breast registered to the Department of Radiotherapy at TD Medical College Hospital, Alappuzha would be taken into this study. The ER, PR and HER2/ErbB2 receptor in the tumour cell of these patients were assessed in the Department of Pathology in this Hospital. The patients were categorised as triplenegative if they are negative for ER, PR and HER2/ErbB2 (Cut-off of less than 1% positive tumour cells). The human epidermal growth factor receptor 2 is assessed by means of IHC or FISH. Immunohistochemistry is scored on a qualitative scale from 0 to 3+ based on interpretation of membranous staining intensity where 0 and 1+ is classified as negative, 2+ as borderline and 3+ as positive. HER2 (++) tissues are reevaluated by FISH analysis and if the HER2 gene amplification copy-to-CEP17 ratio greater than 2.0 was accepted as HER2 positive. Tumour's pathological diagnosis are according to the WHO histological classification of breast tumour grade according to the modified Patley-Scarff scoring system and clinical stage according to the TNM criteria (Tumour-nodemetastasis). confirmed by surgery and pathological examination are taken for this study. These patients were treated with surgery, chemotherapy and radiation based on recommendation of the National Comprehensive Cancer Network Guidelines. Human epidermal growth factor receptor 2 positive patients were managed with trastuzumab or lapatinib and hormone receptor-positive patients were managed with hormone receptor-targeted therapies such as tamoxifen or aromatase inhibitors. The patient's clinicopathological data and necessary investigations will be collected from case records in our department. Patient's follow-up were done once in two months initially, then the duration were increased to once in four months and then once in six months by regular clinical examination and necessary investigations in our outpatient department. Separate proforma will be filled for each patient and all those patients who fulfil the inclusion criteria will be categorised into their ER/ PR/ HER2 status. Relevant characteristics of these two groups for the last five years will be compared. During follow-up patients might have recurrence or metastasis or death. Among these patients, probabilities of death from this cancer and other causes in the presence of competing risks (patients may have developed diabetic, renal, cardiac and neurological diseases during that period) were optimal measures of prognosis.
Inclusion Criteria

Statistical Method
All statistical calculations were performed using the SPSS 17.0 statistical software. Data analysis was done by using Pearson's Chi-square test. To compare the demographics and tumour characteristics between the patients with triplenegative breast cancer and non-triple negative breast cancer using a χ 2 -test for frequencies. For all analyses, p-values were two-sided and considered to be statistically significant if pvalues were < 0.05.
Disease Free Interval
Is calculated in months by using the subject's date of completion of Chemotherapy and/ or Radiotherapy and one of the following: (a) Clinical evidence of Loco-regional recurrence and (b) Clinical and/ or Radiological evidence of systemic recurrence of breast cancer.
Local Recurrence
Is defined as the recurrence occurring in the affected side of breast or regional lymph node.
Distant Metastasis
Is defined as the clinical or radiographic examination showing as distant spread.
Disease Free Survival (DFS)
It was defined as the time from diagnosis of breast cancer to first loco-regional or distant recurrence.
Overall Survival (OS)
It was the time from breast cancer diagnosis to death. This research showed that 46% of the patients with triple-negative cancer were premenopausal women, the triple-negative patients with age < 35 years old were more than the non-triple-negative cancer. 33, 34 In this study histological grade of triplenegative cancer was similar with non-triple-negative cancer, but the rate of the people who had the family history of breast cancer, the rate of lymphatic invasion and larger tumour size (more than 5 centimetres) in triple-negative cancer was higher than that of in non-triple-negative cancer that was statistically significant. 34 The incidence of local recurrence and metastases to organs and death in the triple-negative patients was much higher than that in the non-triple-negative cancer patients during the first 5 years after diagnosis. The rate of visceral organs metastases was higher than the rate of bone metastases. The rate of lung and brain metastases in triple-negative group were all higher than those in the non-triple-negative group, but differed not significantly. During the 5-years period of observation, in 24 patients there occurred recurrence and metastasis in triple-negative group and 13 patients in the non-triple-negative group. In this study, local relapse and metastases occurred earlier in triple-negative patients. In this study those patients with the family history of breast cancer, premenopausal women, larger tumour size (more than 5 centimetres), higher clinical stage, high grade and lymphatic invasion had higher rate of local recurrence and metastasis in triplenegative group than that in the non-triple-negative group that was statistically significant. The 5-years Disease-Free Survival in difference characteristics of each groups were studied. The Disease-Free Survival was lower in triple-negative group than those in non-triple-negative group. During the 5 years' period of observation, patients with the family history of breast cancer and small tumour size (less than 5 centimetres), the 5 years Disease-Free Survival was more in nontriple-negative patients than in triple-negative patients that was statistically significant. During the 5 years period of observation, overall survival was lower in triple-negative group than those in non-triplenegative group. Patients with older age, post-menopausal women, family history, small tumour size (less than 5 cm), higher histologic grade and stage, the 5 years overall survival, more in non-triple-negative patients than in triple-negative patients that was statistically significant.
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DISCUSSION
Triple-negative breast cancer was a distinct subgroup of breast cancer with particular clinico-pathologic behaviour. Compared with the non-triple-cancer, triple-negative breast cancer was characterised by larger tumour size, more positive axillary lymph node, higher clinical stage and higher histological grade, higher tendency for metastasis and lower disease-free survival and overall survival rate which were consistent with previous reports. 16, [33] [34] These characters played the important roles in judging the prognosis of triplenegative breast cancer patients.
In this study age less than 35 years old patients were more in triple-negative than the non-triple-negative groups, which were consistent with previous reports. Some studies reported that the triple-negative group had the higher rate of the family history of breast cancer than the rate in non-triplenegative group. In this study the rate of the people who had the family history of breast cancer in triple-negative group was statistically significant, higher than that in the nontriple-negative group. The result suggested that triplenegative cancer patients have the familial inheritance tendency.
Dent et al 18 conducted a long-term follow-up of 1608 breast cancer patients and found that the incidence of metastases to visceral organs in the triple-negative patients was much higher than that in the non-triple-negative patients during the first 5 years after diagnosis. Lin et al 35 analysed the sites of distant recurrence in 116 metastatic triplenegative patients and reported that the majority of metastases were in lungs and liver. The brain was the third most common site of recurrence. Rakha et al reported that in a study of 1944 breast cancer patients, local relapse and metastases occurred earlier in triple-negative patients. The rate of visceral organs metastases was higher than the rate of bone metastases. According to our study the lungs, liver and brain were the first three most common sites of metastases and the rate of local relapse and the rate of metastases in these sites, more in triple-negative patients than that in the non-triple-negative patients which all differed not significantly.
Bauer et al and other reports 36 showed that clinical stage and histological grade are significantly related to the prognosis of triple-negative cancer, the higher pathological stage and grade of the tumour, the lower the disease-free survival and overall survival of the patient. In our study nontriple-negative patients with tumour size less than 5 centimetres without lymphatic invasion and any histological grade were found to have more disease-free survival and patients with small tumour size (less than 5 centimetres) had statistically significant 5 years disease-free survival. Patients with older age, post-menopausal women, family history, small tumour size (less than 5 centimetres), higher histologic grade and stage, the 5 years overall survival more in nontriple-negative patients than in triple-negative patients that was statistically significant.
Triple-negative cancer which are resistant to the existing ER, PR and HER2-targeted therapies, sequential chemotherapies remain. It is the only routine treatment option. The microtubule-targeting agent Eribulin improved survival in a randomised trial including patients with triplenegative cancer who received at least two prior lines of chemotherapy. [37] [38] Addition of platinum agents to anthracycline/ taxane neoadjuvant chemotherapy demonstrated statistically significant higher pathological complete response rates (41% vs. 54%; 37% vs. 53%; 26% vs. 51%). [39] [40] [41] The adjuvant trial of olaparib (Poly ADP-ribose polymerase inhibitors) should be considered for high-risk germline BRCA-mutant early-stage triple-negative cancer. The diversity and rarity of potentially targetable mutations in triple-negative cancer slow the progress of developing biologically targeted therapies for this disease. 42 There are many ongoing clinical trials and investigations of the role of immune checkpoint inhibitors, the mTOR inhibitor everolimus and a pan-phosphoinositide 3-kinase PI3K inhibitor, antibody-drug conjugates and other immunetargeted agents in breast cancer. 43, 44 
CONCLUSION
In this study, it was found that reason for the poor prognosis of triple-negative breast cancer patients were special biological characteristics such as younger age, higher rate of breast cancer, family history, bigger tumour size, more advanced clinical stage upon diagnosis, higher rate of lymph node metastasis, higher histological grade, earlier recurrence and metastasis and non-susceptibility to endocrine and targeted therapy. In cases where the cancer is caught in earlier stages and treated effectively, a person has a much higher survival rate than if it is discovered in the later stages, where the cancer has spread or does not respond to treatment. Besides standard surgical and radiation therapy, other treatment modalities to check the mutations at different levels should be developed.
